
Age distribution of PrEP users in France 2016-2021
The number of people getting treatment for pre-exposure prophylaxis (PrEP) against the human immunodeficiency virus (HIV) in France has been rising over the years. Among those who used such a treatment with Truvada or a generic equivalent between January 2016 and June 2021, 15.8 percent were younger than 25 and 1 percent were older than 65 years. During this period, most PrEP users in France were aged 26 to 35.